The FDA has approved rusfertide (Mimrylo, Takeda) to treat erythrocytosis in adults with polycythemia vera. Patients with polycythemia vera overproduce red blood cells, increasing blood viscosity and the risk for life-threatening thrombotic events, including stroke, deep vein thrombosis, and pulmonary embolism. The new medication is for those “whose disease has not been adequately controlled with …
Read More
FDA Approves Rusfertide for Polycythemia Vera
